6-OH-dopa inhibited RAD52 foci formation in response to DNA damage in murine hematopoietic cells deficient in BRCA1 and selectively killed BRCA1 and BRCA2-deficient human cancer cells. This evidence concerns the gene RAD52 and cancer.